References
- Mok T, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10); 947-957.
- Nagashima O, Ohashi R, Yoshioka Y, Inagaki A, Tajima M Koinuma Y, et al. High prevalence of gene abnormalities in young patients with lung cancer. J Thorac Dis. 2013; 5(1): 27-30.
- Van den Bussche CJ, Illei PB, Lin MT, Ettinger DS, Maleki Z. Molecular alterations in non-small cell lung carcinoma of the young. Hum Pathol. 2014; 45(12): 2379-2387.
- Sacher AG, Dahlberg SE, Heng J, Mach S, Jänne PA, Oxnard GR. Lung cancer diagnosed in the young is associated with enrichment for targetable genomic alterations and poor prognosis. JAMA Oncol. 2016; 2(3): 313-320.
- Nishi T, Yokose T, Miyagi Y, Daigo Y, Ito H, Isaka T, et al. Clinicopathological features and EGFR gene mutation status in elderly patients with resected nonsmall-cell lung cancer. BMC Cancer. 2014; 14: 610. 10.1186/1471-2407-14-610.
- Shi Y, Au JS, Thongprasert S, Srinivasan S, Tsai CM, Khoa MT, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014; 9(2): 154-162.